PMV Pharmaceuticals (PMVP) Competitors $1.41 -0.01 (-0.70%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.42 +0.01 (+0.35%) As of 02/21/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PMVP vs. ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, KOD, TVGN, NGNE, and ACIUShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Tevogen Bio (TVGN), Neurogene (NGNE), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Atyr PHARMA Immutep Olema Pharmaceuticals Korro Bio Neumora Therapeutics Y-mAbs Therapeutics Kodiak Sciences Tevogen Bio Neurogene AC Immune Atyr PHARMA (NASDAQ:ATYR) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Does the MarketBeat Community prefer ATYR or PMVP? PMV Pharmaceuticals received 11 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 62.16% of users gave PMV Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes12100.00% Underperform VotesNo VotesPMV PharmaceuticalsOutperform Votes2362.16% Underperform Votes1437.84% Does the media refer more to ATYR or PMVP? In the previous week, Atyr PHARMA had 14 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 14 mentions for Atyr PHARMA and 0 mentions for PMV Pharmaceuticals. Atyr PHARMA's average media sentiment score of 0.89 beat PMV Pharmaceuticals' score of 0.00 indicating that Atyr PHARMA is being referred to more favorably in the media. Company Overall Sentiment Atyr PHARMA Positive PMV Pharmaceuticals Neutral Which has stronger earnings & valuation, ATYR or PMVP? Atyr PHARMA has higher revenue and earnings than PMV Pharmaceuticals. Atyr PHARMA is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$350K1,036.06-$50.39M-$0.94-4.60PMV PharmaceuticalsN/AN/A-$68.96M-$1.00-1.41 Do analysts prefer ATYR or PMVP? Atyr PHARMA currently has a consensus target price of $18.60, suggesting a potential upside of 330.56%. PMV Pharmaceuticals has a consensus target price of $5.50, suggesting a potential upside of 290.07%. Given Atyr PHARMA's higher probable upside, equities analysts plainly believe Atyr PHARMA is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do insiders and institutionals hold more shares of ATYR or PMVP? 61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, ATYR or PMVP? Atyr PHARMA has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Is ATYR or PMVP more profitable? PMV Pharmaceuticals' return on equity of -24.20% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% PMV Pharmaceuticals N/A -24.20%-21.67% SummaryAtyr PHARMA and PMV Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.48M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-1.415.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.326.717.644.62Net Income-$68.96M$138.33M$3.18B$245.85M7 Day Performance1.44%-2.61%-1.99%-2.68%1 Month Performance6.82%-2.32%-0.42%-2.19%1 Year Performance-18.50%-5.31%16.51%12.84% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals2.5519 of 5 stars$1.41-0.7%$5.50+290.1%-16.6%$73.48MN/A-1.4150ATYRAtyr PHARMA2.8166 of 5 stars$3.41-5.0%$19.25+464.5%N/A$286.24M$350,000.00-3.6353Analyst ForecastAnalyst RevisionNews CoverageGap UpIMMPImmutep0.9739 of 5 stars$1.96+0.5%$8.50+333.7%-13.9%$285.30M$5.14M0.002,021Upcoming EarningsOLMAOlema Pharmaceuticals3.2669 of 5 stars$4.97+2.9%$28.75+478.5%-64.0%$284.78MN/A-2.2770KRROKorro Bio0.9143 of 5 stars$30.02+3.2%$144.00+379.7%-51.4%$281.29MN/A0.0070News CoverageGap UpNMRANeumora Therapeutics4.0824 of 5 stars$1.74+3.0%$16.50+848.3%-90.0%$281.11MN/A-0.93108News CoverageYMABY-mAbs Therapeutics2.5848 of 5 stars$6.24+1.1%$20.89+234.8%-65.3%$279.49M$84.82M-11.56150News CoverageKODKodiak Sciences4.2483 of 5 stars$5.26+3.1%$8.00+52.1%-14.6%$276.78MN/A-1.4490Positive NewsTVGNTevogen Bio3.4246 of 5 stars$1.58+1.3%$4.20+165.8%-82.1%$276.58MN/A0.003NGNENeurogene2.2428 of 5 stars$18.42-1.9%$60.83+230.3%-41.7%$273.63M$925,000.000.0090ACIUAC Immune2.2079 of 5 stars$2.74+2.2%$12.00+338.0%-21.0%$271.10M$16.48M-5.96140News CoveragePositive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Atyr PHARMA Alternatives Immutep Alternatives Olema Pharmaceuticals Alternatives Korro Bio Alternatives Neumora Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Kodiak Sciences Alternatives Tevogen Bio Alternatives Neurogene Alternatives AC Immune Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMVP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMVP Stock Alerts